AUG 01, 2019 10:14 AM PDT

Novel Therapy Shows Promise for Acute Migraines

WRITTEN BY: Nouran Amin

In a study published in The New England Journal of Medicine, a novel drug, by the name of rimegepant, was found to eliminate pain and reduce characteristic symptoms of an acute migraine in comparison to over-the counter drugs. The study was carried out by Albert Einstein College of Medicine and Montefiore Health System for a large clinical trial and is now awaiting the approval of rimegepant by the U.S. Food and Drug Administration. "For the first time in nearly three decades, people with migraine not helped by existing medications may have a new option to find relief during attacks," says first author, Richard B. Lipton, M.D.

Migraines are debilitating and currently affect about 12 to 14% of people worldwide. It is neurologic disorder characterized by periodic attacks of head pain along with symptoms ranging from feelings of nausea to sensitivity from light and sound. Most sufferers experience at least one migraine attack per month with more than half left severely impaired during their attacks.

Presently, individuals with migraines likely take triptan medications that work to reduce inflammation and constrict blood vessels. These drugs are not beneficial to everyone and can cause intolerable side effect. However, with the novel drug rimegepant, it opens the door for effective and tolerable treatment options besides triptan. "These results confirm that rimegepant's mechanism of action -- blocking the CGRP pathway -- effectively relieves pain and associated symptoms that occur during acute migraine attacks," said Dr. Lipton. "As someone who has studied CGRP blockers for more than a decade, I'm gratified to see their benefits confirmed in a large-scale clinical trial."

Source: Albert Einstein College of Medicine

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 19, 2019
Drug Discovery & Development
SEP 19, 2019
Injectable Hydrogel Recruits Chemotherapeutics to Tumor Site
Targeting tumor cells while avoiding harming healthy tissue remains a growing central challenge in the field of chemotherapeutics. For a while, scientists ...
SEP 19, 2019
Drug Discovery & Development
SEP 19, 2019
Effective Treatment for Ulveal Melanoma
Uveal melanoma is a rare and aggressive type of melanoma that targets the eye and affects an estimated 2,500 people in the United States annually. Nearly h...
SEP 19, 2019
Drug Discovery & Development
SEP 19, 2019
Chemotherapeutics react differently to radiation
Patients with various types of cancer are almost always treated with a combination of chemotherapy and radiotherapy. In chemotherapy, therapeutics consist ...
SEP 19, 2019
Drug Discovery & Development
SEP 19, 2019
Can Psychedelics Treat Alcoholism?
Some of the first research on psychedelics in clinical settings was to assess their efficacy in treating alcoholism. In fact, LSD-based treatments for the ...
SEP 19, 2019
Drug Discovery & Development
SEP 19, 2019
Re-Evaluating a Popular Heart Failure Drug
A recent study found that the popular heart drug--sacubitril/valsartan—holds positive effects on the structure and function of the failing heart. Spe...
SEP 19, 2019
Drug Discovery & Development
SEP 19, 2019
The Three Drugs that Reverse Biological Aging
In the last 100 years, life expectancy in the US has risen from 55 years until 79 (Roser: 2019). And with the continuous development of medicine and scie...
Loading Comments...